Loading…
Lobbying Spend
—
Filings
236
Firms Hired
6
Active Period
2002–2025
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: THORN RUN PARTNERS
Tax issues contained within the Tax Cuts and Jobs Act. H.R.1 - One Big Beautiful Bill Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.1
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: THORN RUN PARTNERS
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. H.R.5376 - Inflation Reduction Act of 2022. International IP issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: THORN RUN PARTNERS
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. H.R.5376 - Inflation Reduction Act of 2022. Issues related to the Prescription Drug User Fee Act (PDUFA).
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs. H.R.5376 - Inflation Reduction Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: THORN RUN PARTNERS
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. H.R.5376 - Inflation Reduction Act of 2022. International IP issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: THORN RUN PARTNERS
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. H.R.5376 - Inflation Reduction Act of 2022. International IP issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: THORN RUN PARTNERS
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. H.R.5376 - Inflation Reduction Act of 2022. International IP issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: THORN RUN PARTNERS
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. H.R.5376 - Inflation Reduction Act of 2022. Issues related to the Prescription Drug User Fee Act (PDUFA).
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs. H.R.5376 - Inflation Reduction Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2022 · second_quarter · Firm: THORN RUN PARTNERS
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031. International IP issues.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2022 · second_quarter · Firm: THORN RUN PARTNERS
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031. International IP issues.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2022 · second_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2022 · second_quarter · Firm: THORN RUN PARTNERS
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031. Issues related to the Prescription Drug User Fee Act (PDUFA).
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2022 · first_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2022 · first_quarter · Firm: THORN RUN PARTNERS
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2022 · first_quarter · Firm: THORN RUN PARTNERS
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2022 · first_quarter · Firm: THORN RUN PARTNERS
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2021 · fourth_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2021 · fourth_quarter · Firm: THORN RUN PARTNERS
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2021 · third_quarter · Firm: THORN RUN PARTNERS
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2021 · third_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 14
Consolidated Appropriations Act, 2021
2020 · fourth_quarter · Firm: THORN RUN PARTNERS
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. H.R. 133, Consolidating Appropriations Act, 2021.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 133
Consolidated Appropriations Act, 2021
2020 · fourth_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs. H.R. 133, Consolidating Appropriations Act, 2021.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 133
Lower Costs, More Cures Act of 2019
2020 · second_quarter · Firm: THORN RUN PARTNERS
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. H.R. 19, Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 19
Lower Costs, More Cures Act of 2019
2020 · second_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs. H.R. 19, Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 19
Source: Senate LDA